Day One Biopharmaceuticals, Inc. (DAWN)

NASDAQ: DAWN · Real-Time Price · USD

Compare

11.35

+0.35 (3.18%)

At close: Feb 13, 2026, 4:00 PM EST

11.36

+0.01 (0.09%)

After-hours: Feb 13, 2026, 7:16 PM EST

DAWN Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	133.67	131.16	-	-	-	-
Cost of Revenue	14.11	5.28	-	-	-	-
Gross Profit	119.56	125.88	-	-	-	-
Selling, General & Admin	116.18	115.45	75.54	61.29	29.16	4.68
Research & Development	169.01	222.7	130.52	85.62	43.58	9.1
Operating Expenses	285.19	338.15	206.06	146.91	72.74	13.78
Operating Income	-165.62	-212.27	-206.06	-146.91	-72.74	-13.78
Interest Expense	-	-	-	-	-	-0.03
Interest & Investment Income	20.38	19.7	17.19	4.75	0	-
Other Non Operating Income (Expenses)	-0.04	109.22	-0.04	-0.02	-0.02	-30.03
EBT Excluding Unusual Items	-145.28	-83.35	-188.92	-142.18	-72.75	-43.84
Other Unusual Items	-	-5	-	-	-	-
Pretax Income	-145.28	-88.35	-188.92	-142.18	-72.75	-43.84
Income Tax Expense	6.47	7.14	-	-	-	-
Earnings From Continuing Operations	-151.76	-95.5	-188.92	-142.18	-72.75	-43.84
Minority Interest in Earnings	-	-	-	-	2.11	3.34
Net Income	-151.76	-95.5	-188.92	-142.18	-70.65	-40.51
Preferred Dividends & Other Adjustments	-	-	-	-	99.99	-
Net Income to Common	-151.76	-95.5	-188.92	-142.18	-170.64	-40.51
Shares Outstanding (Basic)	103	93	80	65	37	6
Shares Outstanding (Diluted)	103	93	80	65	37	6
Shares Change (YoY)	15.45%	16.87%	21.85%	77.13%	568.42%	-6.67%
EPS (Basic)	-1.47	-1.02	-2.37	-2.17	-4.62	-7.33
EPS (Diluted)	-1.47	-1.02	-2.37	-2.17	-4.62	-7.33
Free Cash Flow	-121.36	-80.28	-147.08	-109.9	-48.54	-13.58
Free Cash Flow Per Share	-1.18	-0.86	-1.84	-1.68	-1.31	-2.46
Gross Margin	89.44%	95.97%	-	-	-	-
Operating Margin	-123.90%	-161.84%	-	-	-	-
Profit Margin	-113.53%	-72.81%	-	-	-	-
Free Cash Flow Margin	-90.79%	-61.21%	-	-	-	-
EBITDA	-162.41	-210.71	-206.03	-146.85	-72.72	-13.77
EBITDA Margin	-121.50%	-160.65%	-	-	-	-
D&A For EBITDA	3.21	1.56	0.04	0.06	0.02	0.02
EBIT	-165.62	-212.27	-206.06	-146.91	-72.74	-13.78
EBIT Margin	-123.90%	-161.84%	-	-	-	-
Revenue as Reported	131.16	131.16	-	-	-	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q